Our results suggest a prognostic role of IDO-1 protein expression in NSCLC tumor and immune cells independent of EGFR, KRAS AND PD-L1 expression, and should be explored as a predictive biomarker in clinical studies with IDO-1 targeted therapies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.